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Background
The dopamine transporter (DAT) mediates dopamine
(DA) reuptake once DA gets released into the synaptic
cleft; thereby, the DAT regulates DA content available
for synaptic transmission. Psychostimulants like
amphetamines can induce the reverse operation and
induce outward transport, thereby increasing extracel-
lular dopamine concentrations. Increases of DA in the
synaptic cleft are associated with psychosis and drug
addiction. Influx and efflux of substrate via the DAT
are thought to be asymmetrical and were shown to
possess consensus sites for the regulation by intracellu-
lar kinases. It was demonstrated that the loss of N-
terminal serines ablates amphetamine-induced reverse
transport in the DAT and that Ca
2+/calmodulin-depen-
dent protein kinase IIa (CaMKIIa) can physically bind
the DAT C-terminus and phosphorylate N-terminal
serines. Pharmacological inhibition of CaMKIIa with
KN93 dramatically reduces amphetamine-induced
efflux in both cells stably transfected with the human
DAT and in rat striatal slices. Here we show that
amphetamine-induced DAT-mediated efflux is reduced
in CamKIIa mutants and in a mouse model of Angel-
man syndrome (AS).
Methods
Mouse striatal synaptosomes preloaded with [
3H]MPP
+,
a substrate for the DAT, were superfused using a super-
fusion system. [
3H]MPP
+ release was induced by the
addition of 3 µM D-amphetamine. Superfusates were
collected and quantified using a szintillation counter.
Immunoblots and [
3H]CFT binding experiments were
used to assess DAT protein expression levels. Uptake
assays were performed in striatal synaptosomes using
[
3H]MPP
+ as substrate. For non-specific uptake we used
the DAT-inhibitor mazindol.
Results
Both pharmacological inhibition of CamKIIa or genetic
ablation of CaMKIIa function (in CaMKIIa knock-out
and AS mice) reduces amphetamine-induced reverse
transport in the DAT. As CaMKIIa is one of the brain’s
most abundant proteins involved in a plethora of regula-
tory processes it is not possible to pharmacologically
target it in human AS patients. However, the DAT
w o u l db eap o s s i b l et a r g e ta l s of o rt h e s ep a t i e n t sa n di t
might be promising to further investigate potential DAT
influencing medications to treat Angelman syndrome.
Conclusions
Pharmacologic inhibition of CamKIIa as well as genetic
knock-out or activity-downregulation of CamKIIa
reduce amphetamine-induced reverse transport in the
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